SG11201808849TA - Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative - Google Patents
Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivativeInfo
- Publication number
- SG11201808849TA SG11201808849TA SG11201808849TA SG11201808849TA SG11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA
- Authority
- SG
- Singapore
- Prior art keywords
- box
- rehovot
- international
- science
- york
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320549P | 2016-04-10 | 2016-04-10 | |
| PCT/IL2017/050440 WO2017179053A1 (en) | 2016-04-10 | 2017-04-10 | Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808849TA true SG11201808849TA (en) | 2018-11-29 |
Family
ID=58794130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808849TA SG11201808849TA (en) | 2016-04-10 | 2017-04-10 | Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11278555B2 (https=) |
| EP (1) | EP3442582A1 (https=) |
| JP (2) | JP2019510807A (https=) |
| KR (2) | KR20190008206A (https=) |
| CN (2) | CN118304400A (https=) |
| AU (2) | AU2017250732B2 (https=) |
| BR (1) | BR112018070847A2 (https=) |
| CA (1) | CA3020067A1 (https=) |
| IL (1) | IL262191B2 (https=) |
| MX (2) | MX390751B (https=) |
| RU (2) | RU2021110230A (https=) |
| SG (1) | SG11201808849TA (https=) |
| WO (1) | WO2017179053A1 (https=) |
| ZA (1) | ZA201807187B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10107240B2 (en) | 2014-04-04 | 2018-10-23 | Dayco Ip Holdings, Llc | Check valves and Venturi devices having the same |
| CN106458190B (zh) | 2014-05-30 | 2019-12-06 | 戴科知识产权控股有限责任公司 | 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统 |
| EP3723785A1 (en) * | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
| WO2022149934A1 (ko) * | 2021-01-08 | 2022-07-14 | 가톨릭대학교 산학협력단 | 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE347554T1 (de) | 1998-12-09 | 2006-12-15 | Yeda Res & Dev | Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung |
| IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| IL152900A0 (en) * | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| PT2061512T (pt) | 2006-08-23 | 2020-01-14 | Yeda Res & Dev | Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações |
| US8673270B2 (en) | 2008-10-23 | 2014-03-18 | Steba Biotech S.A. | RGD-containing peptidomimetics and uses thereof |
| WO2012106343A2 (en) * | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| TWI442945B (zh) * | 2011-05-18 | 2014-07-01 | Univ Nat Taiwan | 雙效微脂體用於治療的方法 |
| WO2014141289A1 (en) * | 2013-03-12 | 2014-09-18 | Amrita Vishwa Vidyapeetham University | Photo - chemo composition on the basis of microcapsules with a core -shell structure |
-
2017
- 2017-04-10 KR KR1020187032029A patent/KR20190008206A/ko not_active Abandoned
- 2017-04-10 BR BR112018070847A patent/BR112018070847A2/pt not_active Application Discontinuation
- 2017-04-10 CN CN202410235521.9A patent/CN118304400A/zh active Pending
- 2017-04-10 MX MX2018012392A patent/MX390751B/es unknown
- 2017-04-10 US US16/092,742 patent/US11278555B2/en active Active
- 2017-04-10 WO PCT/IL2017/050440 patent/WO2017179053A1/en not_active Ceased
- 2017-04-10 JP JP2018553149A patent/JP2019510807A/ja active Pending
- 2017-04-10 SG SG11201808849TA patent/SG11201808849TA/en unknown
- 2017-04-10 CN CN201780035366.4A patent/CN109862918A/zh active Pending
- 2017-04-10 KR KR1020227034306A patent/KR20220139445A/ko not_active Abandoned
- 2017-04-10 RU RU2021110230A patent/RU2021110230A/ru unknown
- 2017-04-10 RU RU2018139523A patent/RU2747258C2/ru active
- 2017-04-10 CA CA3020067A patent/CA3020067A1/en active Pending
- 2017-04-10 IL IL262191A patent/IL262191B2/en unknown
- 2017-04-10 AU AU2017250732A patent/AU2017250732B2/en active Active
- 2017-04-10 EP EP17726380.3A patent/EP3442582A1/en not_active Withdrawn
-
2018
- 2018-10-10 MX MX2022003190A patent/MX2022003190A/es unknown
- 2018-10-26 ZA ZA2018/07187A patent/ZA201807187B/en unknown
-
2021
- 2021-11-29 JP JP2021193514A patent/JP2022031823A/ja active Pending
-
2022
- 2022-03-21 US US17/700,063 patent/US20220202838A1/en not_active Abandoned
-
2023
- 2023-02-06 AU AU2023200591A patent/AU2023200591A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3020067A1 (en) | 2017-10-19 |
| US20220202838A1 (en) | 2022-06-30 |
| AU2017250732B2 (en) | 2022-11-10 |
| WO2017179053A1 (en) | 2017-10-19 |
| MX2018012392A (es) | 2019-08-21 |
| IL262191B2 (en) | 2025-01-01 |
| RU2747258C2 (ru) | 2021-04-29 |
| IL262191B1 (en) | 2024-09-01 |
| ZA201807187B (en) | 2020-01-29 |
| RU2018139523A (ru) | 2020-05-15 |
| US11278555B2 (en) | 2022-03-22 |
| US20190125769A1 (en) | 2019-05-02 |
| EP3442582A1 (en) | 2019-02-20 |
| MX2022003190A (es) | 2022-04-11 |
| CN109862918A (zh) | 2019-06-07 |
| KR20190008206A (ko) | 2019-01-23 |
| BR112018070847A2 (pt) | 2019-02-05 |
| RU2021110230A (ru) | 2021-05-26 |
| MX390751B (es) | 2025-03-21 |
| JP2022031823A (ja) | 2022-02-22 |
| AU2017250732A1 (en) | 2018-11-15 |
| IL262191A (en) | 2018-11-29 |
| CN118304400A (zh) | 2024-07-09 |
| JP2019510807A (ja) | 2019-04-18 |
| KR20220139445A (ko) | 2022-10-14 |
| AU2023200591A1 (en) | 2023-03-09 |
| RU2018139523A3 (https=) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201903946SA (en) | Devices and methods for slurry generation | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201810440VA (en) | Medical devices, systems and methods utilizing permanent magnet and magnetizable feature | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201804641WA (en) | Methods for generating functional hematopoietic stem cells |